

ELECTROPHORESIS

Supporting Information

for Electrophoresis

DOI 10.1002/elps.200500857

Hong-Lei Huang, Taras Stasyk, Sandra Morandell, Hans Dieplinger,
Gerda Falkensammer, Andrea Griesmacher, Maurice Mogg, Martin Schreiber,
Isabel Feuerstein, Christian W. Huck, Guenther Stecher,
Guenther K. Bonn and Lukas A. Huber

**Biomarker discovery in breast cancer serum using 2-D-DIGE/MALDI-TOF/TOF
and data validation by routine clinical assays**

Supplementary

Table 1

(A)

| Patient ID | Age (years) | Menaupausal status | Diagnosis | Transferrin (mg/dl) | Haptoglobin (mg/dl) | Apolipoprotein A1 (g/d) | Total protein concentration (g/dl) |
|----------------------|-------------|--------------------|--|---------------------|---------------------|-------------------------|------------------------------------|
| controls >60 years | | | | | | | |
| 243 | 72.31 | post | intraductal papilloma | 249.47 | 169.43 | 176.71 | 7.35 |
| 295 | 68.19 | post | fibrocystic mastopathy | 216.55 | 148.75 | 163.93 | 7.55 |
| 261 | 67.40 | post | intraductal papilloma and fibrocystic mastopathy | 200.96 | 106.23 | 153.15 | 8.63 |
| 226 | 65.84 | post | intraductal papilloma | 275.43 | 185.89 | 136.25 | 7.85 |
| 336 | 62.83 | post | fibrocystic mastopathy, low grade | 222.67 | 188.78 | 142.80 | 9.47 |
| 251 | 62.13 | post | Fibrocystic mastopathy | 241.36 | 108.61 | 164.31 | 8.23 |
| 325 | 62.12 | post | fibroadenoma | 225.08 | 105.57 | 158.51 | 7.23 |
| 264 | 61.40 | post | fibrocystic mastopathy | 225.24 | 169.44 | 211.04 | 7.53 |
| 17 | 60.10 | post | healthy | 259.43 | 188.96 | 168.53 | 7.48 |
| controls 50-60 years | | | | | | | |
| 344 | 59.14 | post | fibrocystic mastopathy | 224.98 | 186.55 | 149.99 | 8.15 |
| 210 | 58.20 | post | fibrocystic mastopathy | 226.94 | 92.93 | 196.13 | 7.44 |
| 347 | 57.56 | post | fibrocystic mastopathy | 234.74 | 122.20 | 152.98 | 8.69 |
| 4 | 57.40 | post | healthy | 242.85 | 136.47 | 234.25 | 7.11 |
| 257 | 56.50 | post | intraductal papilloma | 258.00 | 71.95 | 274.35 | 7.11 |
| 16 | 56.40 | post | healthy | 223.41 | 173.64 | 215.31 | 6.60 |
| 326 | 56.05 | post | | 259.70 | 232.76 | 161.64 | 7.09 |
| 6 | 54.30 | post | healthy | 267.13 | 103.11 | 193.47 | 6.95 |
| 11 | 52.50 | post | healthy | 288.62 | 230.70 | 153.80 | 7.65 |
| controls 40-50 years | | | | | | | |
| 208 | 46.11 | pre | endometrium polyp | 272.40 | 212.81 | 201.11 | 7.18 |
| 9 | 45.80 | pre | healthy | 317.90 | 129.24 | 157.39 | 7.33 |
| 12 | 45.30 | pre | healthy | 270.81 | 148.25 | 172.96 | 7.73 |
| 272 | 44.81 | pre | tumor free breast | 234.31 | 115.15 | 145.19 | 7.63 |
| 250 | 44.66 | pre | fibrocystic mastopathy | 236.86 | 117.54 | 176.31 | 8.58 |
| 266 | 44.58 | pre | fibrocystic mastopathy | 253.38 | 284.32 | 140.23 | 7.90 |
| 241 | 44.52 | pre | endometrium cyst | 304.08 | 129.23 | 166.29 | 8.04 |
| 282 | 42.68 | pre | fibrocystic mastopathy left, fibroadenoma right | 219.27 | 171.09 | 179.94 | 7.77 |
| 294 | 40.73 | pre | nodular adenosis | 309.54 | 151.81 | 150.83 | 8.42 |
| 2 | 40.20 | pre | healthy | 232.28 | 127.70 | 161.83 | 8.96 |
| controls <40 years | | | | | | | |

| | | | | | | | |
|---------|-------|-----|---------|--------|--------|--------|------|
| 13 | 39.90 | pre | healthy | 299.09 | 177.36 | 146.81 | 8.04 |
| 3 | 38.40 | pre | healthy | 190.75 | 140.82 | 191.96 | 7.65 |
| 1 | 37.30 | pre | healthy | 237.07 | 145.89 | 171.17 | 7.96 |
| 14 | 35.90 | pre | healthy | 194.13 | 116.90 | 172.68 | 7.32 |
| 15 | 35.80 | pre | healthy | 288.85 | 96.91 | 173.64 | 7.30 |
| 8 | 34.50 | pre | healthy | 299.65 | 61.32 | 163.09 | 7.70 |
| 7 | 29.20 | pre | healthy | 244.09 | 156.52 | 224.58 | 6.98 |
| Average | | | | 249.91 | 148.71 | 174.38 | |

(B)

| Patient ID | Age (years) | Menaupausal status | ER-Status | PgR-Status | pT | pN | Tum-or size (cm) | Grad-ing | Diagnosis | Transfe-rrin (mg/dl) | Hapto-globin (mg/dl) | Apo-A1 (mg/dl) | Total protein concent-ration (g/dl) |
|----------------------|-------------|--------------------|-----------|------------|------|-----|------------------|----------|--|----------------------|----------------------|----------------|-------------------------------------|
| patients >60 years | | | | | | | | | | | | | |
| 287 | 77.07 | post | 1 | 0 | 2 | 1a | 2.5 | 2 | ILC (invasive, lobular mamma carcinoma) | 259.16 | 119.47 | 179.20 | 7.93 |
| 348 | 70.25 | post | 3 | 2 | 1c | 2a | | 2 | ILC (invasive, lobular mamma carcinoma) | 345.23 | 126.65 | 184.87 | 7.48 |
| 299 | 69.74 | post | 3 | 0 | 1c | 0 | 1.2 | 3 | IDC (invasive, ductal mamma carcinoma) | 281.53 | 128.73 | 163.27 | 7.30 |
| 224 | 69.48 | post | | | is | 0 | 0.2 | 1 | DCIS | 291.80 | 150.83 | 199.13 | 7.75 |
| 335 | 68.40 | post | 3 | 1 | 2 | 0 | 3 | 3 | IDC (invasive, ductal mamma carcinoma) | 262.63 | 220.07 | 227.33 | 7.36 |
| 283 | 67.91 | post | 3 | 3 | 1b | 0 | 1 | 3 | IDC (invasive, ductal mamma carcinoma) | 286.14 | 71.44 | 204.11 | 8.01 |
| 339 | 67.60 | post | 3 | 3 | | | | 1 | DCIS | 205.91 | 159.32 | 187.27 | 8.20 |
| 308 | 65.89 | post | 3 | 2 | | | | 3 | IDC (invasive, ductal mamma carcinoma) | 299.98 | 129.21 | 228.08 | 6.80 |
| 297 | 60.89 | post | 3 | 2 | 1b | 1mi | 0.8 | 1 | IDC (invasive, ductal mamma carcinoma) | 246.12 | 183.57 | 184.59 | 7.45 |
| 209 | 60.23 | post | 0 | 0 | 2 | 1a | 4.5 | 3 | IDC (invasive, ductal mamma carcinoma) | 254.67 | 107.44 | 189.01 | 7.68 |
| patients 50-60 years | | | | | | | | | | | | | |
| 270 | 58.65 | post | 2 | 2 | 1c | 0 | 1.7 | 2 | ILC (invasive, lobular mamma carcinoma) | 290.49 | 242.07 | 207.83 | 6.47 |
| 237 | 56.61 | post | 3 | 0 | 2 | 0 | | 2 | DCIS | 242.32 | 114.28 | 186.24 | 7.22 |
| 316 | 56.56 | post | | | 1b | 0 | 0.4 | 1 | invasive adenocarcinoma of the endometrium | 272.78 | 169.21 | 159.98 | 7.45 |
| 267 | 56.39 | post | 0 | 0 | 1mic | 0 | 5.5 | 3 | DCIS, microinvasive | 206.62 | 223.91 | 192.20 | 7.95 |
| 286 | 55.07 | post | 3 | 2 | 1c | 1a | 1.2 | 2 | ILC (invasive, lobular mamma carcinoma) | 256.55 | 145.66 | 179.49 | 8.13 |
| 223 | 54.98 | post | 2 | 0 | 2 | 0 | 3 | 1 | IDC (invasive, ductal mamma carcinoma) | 286.50 | 185.79 | 200.55 | 8.80 |

| | | | | | | | | | | | | | |
|----------------------|-------|------|---|---|------|-----|-----|-----|---|--------|--------|--------|------|
| | | | | | | | | | carcinoma) | | | | |
| 222 | 53.79 | post | 2 | 3 | 1a | 0 | 0.5 | 1 | Invasive, lobular adeno carcinoma | 339.56 | 96.55 | 244.48 | 6.75 |
| 258 | 53.40 | post | 3 | 0 | 1c | 0 | 1.2 | 1 | IDC (invasive, ductal mamma carcinoma) | 328.32 | 178.23 | 186.57 | 7.33 |
| 205 | 52.34 | post | 0 | 0 | is | 0 | 2 | 2 | DCIS | 200.94 | 116.05 | 183.75 | 8.41 |
| 236 | 51.82 | post | 2 | 2 | 1b | 0 | 3 | 3 | DCIS, extensive | 255.97 | 185.63 | 175.86 | 7.82 |
| 298 | 50.26 | post | 0 | 0 | 1c | 0 | 2 | 3 | IDC (invasive, ductal mamma carcinoma) | 208.36 | 212.51 | 162.75 | 7.37 |
| patients 40-50 years | | | | | | | | | | | | | |
| 345 | 49.10 | pre | 0 | 2 | | | | 1-2 | DCIS | 294.70 | 92.04 | 166.53 | 7.57 |
| 232 | 47.98 | pre | 3 | 2 | 2 | 3a | 3.8 | 3 | IDC (invasive, ductal mamma carcinoma) | 232.29 | 75.86 | 132.48 | 6.94 |
| 309 | 47.56 | pre | 0 | 0 | 4d | 1a | | 3 | IDC (invasive, ductal mamma carcinoma) | 277.12 | 162.86 | 106.58 | 7.75 |
| 235 | 47.02 | pre | 2 | 2 | is | 0 | | 1 | DCIS | 276.67 | 169.78 | 201.22 | 7.29 |
| 206 | 46.63 | pre | 2 | 2 | | | 1.3 | | DCIS | 297.18 | 65.33 | 156.41 | 6.35 |
| 239 | 45.71 | pre | 1 | 1 | 1a | 1mi | 4 | 3 | DCIS | 259.80 | 177.05 | 185.71 | 7.94 |
| 321 | 45.54 | pre | 1 | 1 | 1c | 0 | 3 | 2 | IDC (invasive, ductal mamma carcinoma) | 299.38 | 105.48 | 150.22 | 7.12 |
| 303 | 45.10 | pre | 3 | 3 | 2 | 0 | 3.5 | 2 | ILC (invasive, lobular mamma carcinoma) | 254.03 | 94.90 | 180.22 | 7.97 |
| 306 | 44.66 | pre | 2 | 1 | 1c | 0 | 1.4 | 1 | DCIS | 248.65 | 211.55 | 154.40 | 7.62 |
| 302 | 41.26 | pre | 0 | 0 | 1mic | 0 | 0.5 | 3 | DCIS | 295.92 | 95.66 | 191.54 | 7.10 |
| 262 | 40.30 | pre | 2 | 0 | is | 0 | 5 | 3 | DCIS | 237.14 | 70.09 | 207.49 | 7.99 |
| patients <40 years | | | | | | | | | | | | | |
| 322 | 36.45 | pre | 0 | 0 | 2 | 0 | | 3 | ductal mamma carcinoma | 295.14 | 311.92 | 213.21 | 7.74 |
| 273 | 36.44 | pre | | | is | | 1.2 | 2 | DCIS | 212.42 | 52.42 | 183.25 | 8.38 |
| 193 | 34.14 | pre | 0 | 0 | 1b | 1a | 0.7 | 3 | IDC (invasive, ductal mamma carcinoma) | 249.57 | | 207.19 | 6.49 |
| 313 | 33.68 | pre | 0 | 2 | 2is | 1mi | 3 | 3 | DCIS, moderately sized | 376.81 | 93.11 | 273.01 | 7.36 |
| 200 | 32.12 | pre | 2 | 2 | 1c | 1a | 2.4 | 3 | IDC (invasive, ductal mamma carcinoma) | 291.57 | 153.17 | 156.86 | 8.28 |
| 230 | 31.98 | pre | 0 | 0 | 2 | 0 | 2.2 | 3 | IDC (invasive, ductal mamma carcinoma) | 238.51 | 91.98 | 152.04 | 7.28 |
| 259 | 31.7 | pre | 1 | 0 | 1b | 0 | 2 | 3 | IDC (invasive, ductal mamma carcinoma) | 252.16 | 63.98 | 202.29 | 8.12 |
| Average | | | | | | | | | | 269.50 | 140.89 | 185.83 | |

Table 1. Individual immunochemical quantification by standard clinical diagnostics of 3 candidate proteins transferrin, haptoglobin and apolipoprotein AI concentration in 35 control (A) and 39 breast cancer patients (B).